CC-401 hydrochloride CC401 HCl,99.46%
产品编号:Bellancom-13022| CAS NO:1438391-30-0| 分子式:C22H25ClN6O| 分子量:424.93
CC-401 hydrochloride 是一种有效的 JNK 抑制剂,Ki 为 25 到 50 nM。
本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用,
CC-401 hydrochloride CC401 HCl
产品介绍 | CC-401 hydrochloride 是一种有效的 JNK 抑制剂,Ki 为 25 到 50 nM。 | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
生物活性 | CC-401 hydrochloride is a potent inhibitor of all three forms of JNK with Ki of 25 to 50 nM. | ||||||||||||||||
体外研究 |
CC-401 has at least 40-fold selectivity for JNK compared with other related kinases, including p38, extracellular signal-regulated kinase (ERK), inhibitor of κB kinase (IKK2), protein kinase C, Lck, zeta-associated protein of 70 kDa (ZAP70). In cell-based assays, 1 to 5 μM CC-401 provides specific JNK inhibition. CC-401, a small molecule that is a specific inhibitor of all three JNK isoforms. CC-401 competitively binds the ATP binding site in JNK, resulting in inhibition of the phosphorylation of the N-terminal activation domain of the transcription factor c-Jun. The specificity of this inhibitor is tested in vitro using osmotic stress of the HK-2 human tubular epithelial cell line. CC-401 inhibits sorbitol-induced phosphorylation of c-Jun in a dosage-dependent manner. However, CC-401 does not prevent sorbitol-induced phosphorylation of JNK, p38, or ERK. 西域 has not independently confirmed the accuracy of these methods. They are for reference only. | ||||||||||||||||
体内研究 |
The staining of p-JNK is moderately induced in bevazicumab and Oxaliplatin treatments as compared to control, and in the CC-401-treated samples p-cJun content is significantly lower, consistent with effective JNK inhibition. DNA damage is modestly elevated in combined treatments with CC-401. CC-401 treatment from days 7 to 24 slows the progression of proteinuria, which is significantly reduced compared to the no-treatment and vehicle groups at days 14 and 21. However, there is still an increase in the degree of proteinuria at day 21 in CC-401-treated rats compared to proteinuria at day 5. The vehicle and no-treatment groups developed renal impairment at day 24 as shown by an increase in serum creatinine. This is prevented by CC-401 treatment. 西域 has not independently confirmed the accuracy of these methods. They are for reference only. | ||||||||||||||||
体内研究 |
The staining of p-JNK is moderately induced in bevazicumab and Oxaliplatin treatments as compared to control, and in the CC-401-treated samples p-cJun content is significantly lower, consistent with effective JNK inhibition. DNA damage is modestly elevated in combined treatments with CC-401. CC-401 treatment from days 7 to 24 slows the progression of proteinuria, which is significantly reduced compared to the no-treatment and vehicle groups at days 14 and 21. However, there is still an increase in the degree of proteinuria at day 21 in CC-401-treated rats compared to proteinuria at day 5. The vehicle and no-treatment groups developed renal impairment at day 24 as shown by an increase in serum creatinine. This is prevented by CC-401 treatment. 西域 has not independently confirmed the accuracy of these methods. They are for reference only. | ||||||||||||||||
性状 | Solid | ||||||||||||||||
溶解性数据 |
In Vitro:
DMSO : 100 mg/mL (235.33 mM; Need ultrasonic) H2O : 12.5 mg/mL (29.42 mM; Need ultrasonic) 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:
——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
| ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) | ||||||||||||||||
参考文献 |
|
产品名: | CC-401 hydrochloride |
CAS号: | 1438391-30-0 |
制造商/供应商: | 西域试剂 网站:www.hzbp.cn 邮件:13911702513@139.com |
2. 合成/成分数据
产品名: | CC-401 hydrochloride |
别名: | CC401 HCl |
分子式: | |
分子量: | 424.93 |
3. 急救措施
吸入后: | 如果吸入,移至空气新鲜处,如果呼吸困难,给输氧,如呼吸停止,给予人工呼吸。 |
皮肤接触后: | 用大量的水冲洗,移除污染的衣服和鞋子。 |
眼睛接触后: | 检查并取下隐形眼镜,并用大量的水冲洗;呼叫医生。 |
吞食后: | 如果吞食,用大量纯净水漱口;呼叫医生。 |
4. 消防措施
适当的灭火剂: | 雾状水,二氧化碳,干粉或泡沫。 |
防护设备: | 穿戴自给式呼吸器和防护服,以防止与皮肤和眼睛接触。 |
5. 泄漏应急处理
安全防范措施: | 封锁泄漏区域;穿戴自给式呼吸器,防护服和厚橡胶手套。 |
清洁/收集措施: | 使用液体粘合原料(硅藻土,通用粘合剂)吸取精细粉末; 使用酒精擦洗表面和设备除去污渍; 根据第11条处理被污染的材料。 |
6. 处理和储存
安全处理说明: | 避免吸入和接触皮肤,眼睛及衣物;材料可能略微具有刺激性。 |
储存: | 2-8°C, dry, sealed |
7. 接触控制和个人防护
呼吸设备: | NIOSH / MSHA认可的呼吸器。 |
双手保护: | 耐化学腐蚀的橡胶手套。 |
眼睛防护: | 化学安全护目镜。 |
8. 稳定性和反应活性
稳定性: | 按照说明存储是稳定的;避免强氧化剂。 |
热分解/其他要避免的情况: | 避免光和热。 |
9. 毒性资料
急性毒性: | 无可用资料。 |
主要刺激性影响: | 无可用资料。 |
在皮肤上: | 无可用资料。 |
对眼睛: | 无可用资料;可能具有刺激性。 |
10. 生态资料
一般注意事项: | 无可用资料。 |
11. 废弃处置
按照所在国家,省份,县市和地方的法规处置。 |
12. 运输信息
正确的运输名称: | 无 |
非危险品运输: | 这种物质被视为非危险品运输。 |
13. 法规信息
尚未有针对此产品作出的化学安全性评估。 |
14. 其他信息
这种化学品仅供受过训练的,有经验的研究人员在穿戴适当装备和授权允许的情况下进行操作处理。以上信息基于我们目前的知识被认为是正确的,但只适用于作为有经验人员的指导。请咨询您自己的安全顾问,并遵守当地和国家的安全法规。在任何其他没有被警告的情况下,并不意味着绝对没有危险存在。西域生物技术不承担任何使用这种化学品所造成的损害和责任。2023 西域生物技术版权所有。 |

匹配竞争对手的价格

效率为先

专业经验 贴心服务

50000+库存